DBVT - DBV Technologies S.A.
| Previous close | 10.05 |
| Open | 10.05 |
| Bid | 9.75 x 1000 |
| Ask | 11.40 x 800 |
| Day's range | 9.90 - 10.06 |
| 52-week range | 3.60 - 25.77 |
| Volume | 48,556 |
| Avg. volume | 242,853 |
| Market cap | 716.383M |
| Beta (3Y monthly) | 2.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.27 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.11 |
- Simply Wall St.•2 days ago
If You Had Bought DBV Technologies (EPA:DBV) Stock Three Years Ago, You'd Be Sitting On A 71% Loss, Today
DBV Technologies S.A. (EPA:DBV) shareholders should be happy to see the share price up 18% in the last month. But that...
- Motley Fool•10 days ago
Here's Why Aimmune Therapeutics Fell 7% Today
The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.
- Zacks•last month
DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Zacks•3 months ago
DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in DBV Technologies S.A. (DBVT).
- Motley Fool•4 months ago
Why DBV Technologies Shares Soared Today
Traders cheered after the company announced the pricing details of a stock offering.
- Business Wire•4 months ago
Cohen Milstein Sellers & Toll PLLC Announces Investigation of DBV Technologies S.A.
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.
- Business Wire•5 months ago
Cohen Milstein Announces Investigation of DBV Technologies S.A.
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.
- Business Wire•5 months ago
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against DBV Technologies S.A. (DBVT)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) securities between February 14, 2018 and December 19, 2018, inclusive (the “Class Period”). DBV Technologies investors have until March 18, 2019 to file a lead plaintiff motion.
- Simply Wall St.•5 months ago
Is DBV Technologies S.A. (EPA:DBV) Potentially Underrated?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! DBV Technologies S.A. (EPA:DBV) is a stock Read More...
- GlobeNewswire•5 months ago
DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019
Montrouge, France, February 4, 2019 DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 Novel immunotherapy based on Viaskin technology highlighted as a potential treatment for ...
- Business Wire•5 months ago
Robbins Arroyo LLP: DBV Technologies S.A. (DBVT) Sued for Misleading Shareholders
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of DBV Technologies S.A. filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 14, 2018 and December 19, 2018.
- Business Wire•6 months ago
DBVT INVESTOR NOTICE: Rosen Law Firm Reminds DBV Technologies S.A. Investors of Deadline in First Filed Securities Class Action – DBVT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of DBV Technologies S.A. from February 14, 2018 through December 19, 2018, inclusive of the important March 18, 2019 lead plaintiff deadline in the first-filed class action.
- GlobeNewswire•6 months ago
DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference
Montrouge, France, February 1, 2019 DBV Technologies to Present at the 8 th Annual Leerink Partners Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: ...
- Business Wire•6 months ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In DBV Technologies S.A. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in DBV Technologies, S.A. (“DBV” or the “Company”) (DBVT) of the March 18, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased DBV securities between February 14, 2018 and December 19, 2018 (the “Class Period”). The case, ITO-Stone v. DBV Technologies S.A. et al, No. 19-cv-00525 was filed on January 23, 2019, and has been assigned to Judge Madeline Cox Arleo.
- Business Wire•6 months ago
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DBV Technologies S.A. (DBVT)
Law Offices of Howard G. Smith reminds investors of the March 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) securities between February 14, 2018 and December 19, 2018, inclusive (the “Class Period”). DBV Technologies investors have until March 18, 2019 to file a lead plaintiff motion. Investors suffering losses on their DBV Technologies investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- Business Wire•6 months ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against DBV Technologies S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against DBV Technologies S.A. (“DBV Technologies” or “the Company”) (NASDAQ: DBVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s shares between February 14, 2018 and December 19, 2018, inclusive (the “Class Period”), are encouraged to contact the firm before March 18, 2019.
- Business Wire•6 months ago
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against DBV Technologies S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against DBV Technologies S.A. (“DBV Technologies” or “the Company”) (NASDAQ: DBVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s shares between February 14, 2018 and December 19, 2018, inclusive (the “Class Period”), are encouraged to contact the firm before March 18, 2019.
- Business Wire•6 months ago
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of DBV Technologies S.A. Investors (DBVT)
Glancy Prongay & Murray LLP (“GPM”), a global investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) securities between October 22, 2018 and December 19, 2018, inclusive (the “Class Period”). DBV Technologies investors have until March 18, 2019 to file a lead plaintiff motion. On December 19, 2018, DBV Technologies revealed that, following discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut was voluntarily withdrawn.
- GlobeNewswire•6 months ago
DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF REGULATED INFORMATION Montrouge, France, January 17, 2019 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock ...
- Business Wire•6 months ago
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of DBV Technologies S.A. Investors (DBVT)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased DBV Technologies S.A. (NASDAQ: DBVT) (“DBV Technologies” or the “Company”) securities between October 22, 2018 and December 19, 2018, inclusive (the “Class Period”). DBV Technologies investors have until March 18, 2019 to file a lead plaintiff motion. On December 19, 2018, DBV Technologies revealed that, following discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut was voluntarily withdrawn.
- Business Wire•6 months ago
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against DBV Technologies S.A. – DBVT
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of DBV Technologies S.A. from February 14, 2018 through December 19, 2018, inclusive .
- GlobeNewswire•6 months ago
DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations ...
- GlobeNewswire•7 months ago
DBV Technologies Expands and Strengthens Leadership Team
DBV`s Chief Scientific Officer (CSO), Dr. Hugh Sampson, will also assume the role of interim Chief Medical Officer (CMO) effective today. Dr. Sampson succeeds Dr. Lucia Septien-Velez, who has decided to leave to pursue other opportunities.
